Skip to main content

7 Result(s)

within J.-B. Bachet Remove this filter

and

  1. Article

    Open Access

    DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

    There is an increasing interest for Notch signalling pathway and particularly Delta-like ligand 4 (DLL4) as potential therapeutic target to improve outcome for patients with pancreatic ductal adenocarcinoma (P...

    A Drouillard, F Puleo, J B Bachet, S Ouazzani, A Calomme… in British Journal of Cancer (2016)

    Download PDF (516 KB) View Article

  2. No Access

    Article

    Recommandations pour la pratique clinique Cancer du rectum

    Le cancer du rectum avec métastases synchrones regroupe un large éventail de présentations cliniques. Dans cette situation, la stratégie thérapeutique va dépendre du site et de l’extension de la tumeur du rect...

    J. -B. Bachet, F. Cauchy, E. Cotte, A. Brouquet in Côlon & Rectum (2016)

  3. No Access

    Article

    Le point sur hENT1, autres biomarqueurs

    La mise en évidence de biomarqueurs prédictifs et/ou pronostiques a permis des avancées majeures ces dernières années en oncologie, permettant de définir de nouvelles cibles thérapeutiques ou de mieux utiliser...

    J.-B. Bachet in Oncologie (2015)

  4. No Access

    Article

    Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm

    Cutaneous adverse events induced by epidermal growth factor receptor (EGFR) inhibitors can hamper the patients' quality of life. The aim of our work was to draft an algorithm for the optimised management of th...

    Z. Reguiai, J. B. Bachet, C. Bachmeyer, L. Peuvrel… in Supportive Care in Cancer (2012)

  5. No Access

    Article

    Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

    Advances in the understanding of the mechanisms involved in oncogenesis have led to the development of so-called targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors, which take on an ...

    L. Peuvrel, C. Bachmeyer, Z. Reguiai, J. B. Bachet, T. André… in Supportive Care in Cancer (2012)

  6. No Access

    Chapter

    Tumeurs digestives : côlon — rectum

    Les cancers colorectaux (CCR) sont la deuxième cause de mortalité par cancer en France et un problème de santé publique [1]. La chirurgie est le traitement curatif de référence du CCR mais, pour les patients n...

    J.-B. Bachet, J. Taïeb, E. Mitry, P. Rougier in Thérapeutique du cancer (2011)

  7. Article

    Open Access

    Prognosis and predictive value of KIT exon 11 deletion in GISTs

    KIT exon 11 mutations are observed in 60% of gastrointestinal stromal tumours (GIST). Exon 11 codes for residues Tyr568 and Tyr570, which play a major role in signal transduction and degradation of KIT. Our aim w...

    J-B Bachet, I Hostein, A Le Cesne, S Brahimi, A Beauchet… in British Journal of Cancer (2009)

    Download PDF (518 KB) View Article